Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients

Figures & data

Table 1 Patient demographics, number of pamidronate cycles per patient, and baseline creatinine and calcium concentrations (mean ± SD, range within parenthesis)

	Total	Female	Male
No of pat. identified	79	29 (37%)	50 (63%)
Mean age at diagnosis (years)	68 ± 10.4 (38–88)	70 ± 8.7 (53–86)	67 ± 11.1 (38–88)
No. of pamidronate cycles/no pat.	10.7 ± 7.1 (1–31)	8.8 ± 5.8 (1–25)	11.8 ± 7.6 (1–31)
S-Cr (μmol/L)	99.8 ± 37.8 (52–267)	87 ± 23.7a (52–160)	107.5 ± 42.7a(54–267)
Total S-Ca (mmol/L)	2.53 ± 0.19 (2.24–3.02)	2.51 ± 0.14 (2.24–2.94)	2.54 ± 0.21 (2.24–3.02)

^a The difference in baseline S-Cr between the two sexes is significant (p < 0.03).

Abbreviations: S-Cr, serum creatinine; S-Ca, serum calcium.

Table 2 Events of serum creatinine increase, infusion related events (inclusive adverse, exclusive osteonecrosis of the jaw), hypocalcemia (<2.32 mmol/L) such as S-Cr and S-Ca range under treatment in 79 patients with multiple myeloma given one hour pamidronate 90 mg infusion. For each parameter, the number of infusions with evaluable data are used

	Total	Female	Male
S-Cr increasing events/no infusions	17/790 2.2%	2/245 0.8%	15/545 2.8%
S-Cr increasing events/no patients	7/79 8.9%	2/29 6.9%	5/50 10%
S-Cr range during treatment (μmol/L)	37–333	37–175	44–333
Events related to the infusion/no infusions	7/846 0.8%	2/256 0.8%	5/590 0.9%
Events related to the infusion/no patients	6/79 7.6%	2/29 6.9%	4/50 8%
Hypocalcemia events/no infusions	69/669 10.3%	8/209 3.8%	61/460 13.3%
Hypocalcemia events/no patients	28/79 35.4%	6/29 20.7%	22/50 44%
S-Ca range during treatment (mmol/L)	2.09–3.94	2.18–3.94	2.09–3.28

Abbreviations: S-Cr, serum creatinine; S-Ca, serum calcium.